Learn More

Archive

Texas Consumable Hemp Program Rules Are Under Review

By Daniel Molina, Shawn Hauser
Apr 9, 2024

Every four years, Texas agencies must review adopted rules and that time has come for the Lone Star State's Consumable Hemp Program. As businesses and consumers navigate the Texas hemp market, it's important to understand the rules, rulemaking process, and impending deadlines. If you participate in Texas' booming hemp market, now is the time to make your voices heard as the comment period for this rule review is open through April 22, 2024.

Shawn Hauser Dives into Federal Cannabis Reform with Opus Consulting

Dec 21, 2023

Shawn Hauser recently joined the “One Minute With…” podcast hosted by Jacques Santucci of Opus Consulting to discuss Vicente LLP’s history with cannabis legalization, the recent recommendation by the HHS to reschedule marijuana to a Schedule III drug and what this means for the future of federal drug policy reform. Listen now!

US Officially Recognizes Medical Use and Safety of Cannabis: The Top 6 Things to Know About Schedule III and the Process Ahead

By Shawn Hauser
Aug 31, 2023

The federal government formally acknowledged the medical use and low potential of abuse for cannabis, with the US Department of Health and Human Services recommending that cannabis be rescheduled to Schedule III under the Controlled Substances Act. While placement in Schedule III still criminalizes commercial cannabis activity at the federal level, it is a significant step on the path to ending prohibition. This rescheduling would eliminate the application of 280E tax penalties, reduce the level of criminal liability for cannabis-related activity, reduce barriers to research, legitimize the industry through gaining credibility and engagement by physicians and the medical community, and support a growing industry for the American economy.

DEA Proposes to Reschedule Hemp-Derived Cannabinoids

By Michelle Bodian, Shawn Hauser, Shane Pennington
May 11, 2023

At a DEA supply chain conference last week, Terrance Boos, Section Chief, Drug and Chemical Evaluation Section, stated that the DEA will be releasing a rule to reschedule certain hemp-derived cannabinoids.

[Webinar] Psychedelic Opportunities in Oregon and Colorado

Jan 12, 2023

As states like Oregon and Colorado develop regulated pathways for people to get involved in the regulated psychedelics industry, possibilities—and questions—are increasing: What are the opportunities now, what’s next, and where? Get answers by watching this recorded session.

Colorado Prop 122: A Transformative Measure Grounded in Equity and Healing

By Joshua Kappel and Tucker Wentz
Oct 11, 2022

Vicente Sederberg LLP is proud to stand with Natural Medicine Colorado and support Proposition 122. This measure not only provides safe access to natural psychedelic medicines, but does so in a way that is grounded in equity and conscious capitalism while also protecting legacy communities and existing medicine keepers.

The Natural Medicine Health Act of 2022: A Measure to Access Psychedelic Medicine in Colorado

By Colleen Mitchell, Yolanda Clarke
Oct 10, 2022

Prop 122 would create a regulated system for adults aged 21 and older to access natural psychedelic medicine, such as psilocybin, in a supervised setting to treat various mental health conditions. It would also allow for the cultivation, possession, personal use, and gifting of psychedelic medicine for adults aged 21 and older. Read this for an overview of the proposition’s key components.

Lessons Learned from the Regulation of CBD Products in the United Kingdom

By Shawn Hauser, Catie Wightman, Ariane Beckman
Sep 20, 2022

Like the US, regulators in the UK are struggling to find ways to best regulate CBD and other hemp-derived products—frustrating hemp businesses across the globe. Read this VS Insights article to learn how the UK is currently regulating CBD and key findings and recommendations from the ACMD's Consumer CBD Products Report.

Vicente Sederberg Contributes to APPG for CBD Products' Business Plan to Future-Proof UK Cannabis Industry

Jul 28, 2022

The All-Party Parliamentary Group (APPG) for CBD Products recently delivered "A Plan for a Legal and Regulated UK Hemp and Cannabis Sector" to the UK Government. Shawn Hauser and Andrew Livingston contributed to the business plan, which offers an industry analysis and series of recommendations to create a well-regulated, multi-faceted and competitive UK cannabis industry.

FDA Enforcement Action Targeted at Hemp-Derived Delta-8 Products

By Michelle Bodian, Shawn Hauser, Catie Wightman
May 5, 2022

For the first time ever, the FDA issued warning letters to companies selling products containing hemp-derived Delta-8 THC. Notably, this is the first time the FDA has specifically enforced against Delta-8 products. Read this for key takeaways from these warning letters.

[Webinar] Minor Cannabinoids & Trending Topics in Hemp

Apr 1, 2022

Watch this session exploring trending topics in hemp. During the session, members of our hemp team dive into the legality, regulation, and lawsuits surrounding minor cannabinoids, current federal hemp legislation, and what we expect and hope to see in the 2023 Farm Bill.

ABA Global Business of Cannabis Conference is Coming to Denver

Nov 9, 2021

The American Bar Association's International Law Section will host its first annual Global Business of Cannabis Conference in Denver, Colorado from November 10-12, 2021. Marc Ross is slated to join the panel "The Environmental Impact of Cannabis Cultivation: Does Legalization Make a Difference?"

Cannabis Entrepreneurship Academy

May 4, 2021

Colorado Law Executive Education and CU Leeds School of Business are offering an online Cannabis Entrepreneurship Academy on Fridays during June 2021. The academy will tackle many cannabis business issues, including leadership, financing, regulations, markets, and more!

5 Things You Need to Know Before Entering the Cannabis Industry

By Brian Vicente
Apr 19, 2021

The cannabis industry is complex. Prospective cannabis business owners and other service providers interested in working with cannabis businesses are wise to take a step back and assess what it really takes to not only enter the cannabis industry, but to succeed in it.

Commercial Leases Involving Cannabis Businesses

By Ben Leonard and Brett Williams
Mar 9, 2021

This article published by the Colorado Bar Association addresses issues unique to cannabis-related business lease transactions and offers suggestions for structuring such leases to maintain regulatory compliance.

Coronavirus and Cannabis: Colorado Regulatory Updates

By Charles Alovisetti, Corey Cox, Justin Johnson, Andrew Livingston, Jessica Scardina, Jordan Wellington, Catie Wightman
Jan 11, 2021

Vicente Sederberg is monitoring the potential impact of the coronavirus (COVID-19) on cannabis businesses, service providers, and consumers in Colorado.

Colorado Cannabis Expungement Clinic

Jun 11, 2020

The Color of Cannabis, in partnership with Minority Cannabis Business Association and Vicente Sederberg LLP, will host a free expungement clinic for Denver County cannabis convictions on June 20, 2020. RSVP by June 19!

What’s Next for Texas Hemp?

By Shawn Hauser
May 19, 2020

With its incredible farming communities, over 100 million acres of farmland, and large manufacturing and research infrastructure, Texas is poised to play a significant role in the U.S. hemp industry.

[Webinar] Hemp Game Changers

Apr 17, 2020

This virtual session, originally planned for SXSW 2020, features representatives from Vicente Sederberg, Canopy Growth Corporation, and Willie's Remedy discussing the future of the industry, its challenges, the environment, and more.

How to Get a Medical Marijuana Card via Telemedicine

By Charles Alovisetti, Brandon Kurtzman
Apr 16, 2020

Since COVID-19 has limited patient ability to get in-person consultations and examinations with health care providers, how does one go about obtaining a medical marijuana patient certification?

Getting to the Root of the Problem: The 0.3% THC Hemp Standard

By Shawn Hauser, Partner
Feb 27, 2020

The beginning of federally regulated hemp has been marred by industry-wide concerns about an overly restrictive federal program, and what may come from the USDA review of more than 4,600 comments to its interim final rule governing U.S. hemp production.